MilliporeSigma Announces Neoclease as Winner of 2025 North American Advance Biotech Grant
Article content
Winner's lead therapy targets Parkinson's disease; platform addresses 6,000+ genetic disorders
Neoclease gains access to MilliporeSigma's technologies and expert support to scale its AI-designed gene-editing platform
The company has awarded 40+ startups globally through Advance Biotech Grant since 2014
Article content
BURLINGTON, Mass. — MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced Neoclease as the winner of the 2025 North American Advance Biotech Grant. The Boston-based biotech startup develops AI-designed gene editing therapies for Parkinson's disease.
Article content
Article content
'We're committed to empowering biotech innovators who are advancing transformative modalities like gene editing,' said Sebastián Arana, Head of Process Solutions, Life Science business of Merck KGaA, Darmstadt, Germany. 'By combining Neoclease's AI-designed gene-editing platform with our technologies, regulatory expertise, and process support, we aim to help accelerate new treatments that minimize side effects and maximize effectiveness for patients.'
Article content
Neoclease's platform combines generative AI and synthetic biology to develop next-generation, precision gene-editing therapies. Neoclease's lead candidate, NCX-L2, is designed to slow or halt the progression of Parkinson's disease – a condition that currently has no disease-modifying treatments. More broadly, Neoclease's approach has the potential to address more than 6,000 monogenic diseases by targeting the root causes of illness rather than only managing symptoms.
Article content
As part of the grant, Neoclease will receive access to MilliporeSigma's products, technologies, and contract testing services, as well as expert consultation and training through the M Lab™ Collaboration Center and Emprove ® program. M Lab™ Collaboration Centers offer hands-on technical solutions and process optimization, while the Emprove ® Program simplifies risk management and regulatory compliance through quality products, detailed documentation, and dedicated support. These resources will support Neoclease in scaling its processes, optimizing manufacturing, and navigating regulatory requirements.
Article content
The Advance Biotech Grant Program, launched in 2014, reflects the ongoing commitment of the life science business of Merck KGaA, Darmstadt, Germany to supporting early-stage biotech companies developing innovative therapies for patients. To date, more than 40 companies worldwide have received grants and technical support across a wide range of therapeutic areas including cancer, neurological diseases, and cardiovascular disorders. The company will continue this global effort with upcoming grant awards in Asia-Pacific (October) and Europe, the Middle East, and Africa (November).
Article content
About the Life Science business of Merck KGaA, Darmstadt, Germany
Article content
The Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has more than 26,000 employees and more than 55 total manufacturing and testing sites worldwide, with a portfolio of more than 300,000 products focused on scientific discovery, biomanufacturing and testing services. Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and electronics.
Article content
Around 62,000 employees work to make a positive difference to millions of people's lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2024, Merck KGaA, Darmstadt, Germany, generated sales of € 21.2 billion in 65 countries.
Article content
The company holds the global rights to the name and trademark 'Merck' internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany, operate as MilliporeSigma in life science, EMD Serono in healthcare and EMD Electronics in electronics. Since its founding in 1668, scientific exploration and responsible entrepreneurship have been key to the company's technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company. For more information about Merck KGaA, Darmstadt, Germany, visit www.emdgroup.com.
Article content
Article content
Article content
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
an hour ago
- Globe and Mail
Prediction: This Monster Stock Can Double in 5 Years
Recent market volatility has had little impact on Netflix (NASDAQ: NFLX). The company's shares are up by 36% this year, even as the S&P 500 is barely in the green. Netflix owes this performance to solid financial results and strong guidance. The streaming specialist is firing on all cylinders, and the best news is that it's not too late to invest in the stock. In the next five years, Netflix's shares could double in value -- and for those keeping score, that's a compound annual growth rate of 14.9%. The path to $1 trillion Netflix's market capitalization is currently $515 billion. Management wants to get to $1 trillion by 2030. There aren't many companies worth that much. All are massively successful leaders in their niches. That description also fits Netflix, which is the undisputed leader in the streaming industry. Of course, that doesn't mean the stock will reach the $1 trillion mark by 2030, but that goal is by no means out of the company's reach. Netflix has several opportunities that could enable it to double key metrics over the next five years. Although it no longer reports exact membership figures in its quarterly updates, membership growth remains a key driver of revenue growth. Netflix also benefited from recent price hikes. The company can afford it thanks to its incredibly strong brand name. It won't lose a significant number of subscribers even as it charges higher fees for its services. In fact, it should continue to gain more. These two factors should drive strong results in the medium term, and there are other factors to consider as well. Netflix launched an ad-supported tier in late 2022, and it recently hit 94 million monthly active users. For context, that's more than Hulu or Apple TV. That's another testament to Netflix's brand power, but its ad service still has massive potential. The streaming specialist has recently introduced various features to enhance its ad business, which should yield benefits in the long run. Between growing subs, rising engagement, and an improving advertising business, Netflix's revenue, earnings, and free cash flow could at least double in the next five years. Beyond 2030 There is more good news for investors. Netflix's prospects are attractive well beyond 2030. The company reported that its ad-supported tier has more 18 to 34-year-olds than any broadcast or cable network in the U.S. That's a significant statistic, and here's why: Though streaming has been replacing cable, the latter isn't dead yet, not by a long shot. It's being kept alive, but primarily by older people who are more likely to have cable. Netflix is the future of entertainment, and it will continue to take over as demographic shifts take hold -- that is, as younger generations account for an increasingly larger percentage of the population. This won't happen overnight. In fact, it could take a few decades. In other words, there remains a substantial long-term opportunity for Netflix. True, it will have to compete with other streaming giants. However, Netflix has remained a leader even as competition has become fiercer. The company's brand name is only one reason for that success. Netflix's content strategy is another factor driving its success. Thanks to its massive ecosystem of users, Netflix can analyze viewing patterns and preferences to help guide the shows and movies it produces. That means successful shows spread rapidly through word of mouth, increase the company's subscribers and engagement, and grant Netflix access to even more data it can use to make even better content -- a classic example of the network effect. Netflix should be able to thrive over the long run despite the proliferation of streaming services. So, while there is a great chance the stock will double in the next five years and reach a $1 trillion valuation, the company's long-term prospects are equally attractive. It's still a great time to invest in Netflix, even after the run it has experienced in the past two years. Should you invest $1,000 in Netflix right now? Before you buy stock in Netflix, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Netflix wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $660,821!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $886,880!* Now, it's worth noting Stock Advisor 's total average return is791% — a market-crushing outperformance compared to174%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 9, 2025
CBC
an hour ago
- CBC
Calgary startup tackles referee abuse with microphones and machine learning
Abuse of referees in amateur sport has been an issue for decades and all sorts of attempts have been made to curb the problem, from sternly worded signs that remind fans to be respectful to green armbands that identify novice officials to body-worn cameras that record footage from the refs' perspectives. Now, a Calgary startup is employing a bit of all those strategies, combined with a type of artificial intelligence known as machine learning, to tackle the issue in a new way. Elements Athletics has launched a product known as Mic'd Up that involves wireless microphones in lightweight armbands worn by refs, coupled with signs that alert players, coaches and spectators that what they say can and will be recorded. The hours of audio caught by these mics would be cumbersome for a human to review, but CEO Mark Lootens says modern machine-learning techniques allow that process to be automated — and affordable. "That's the cool thing about where we're at right now, from a software development perspective," he said. "Our product didn't make sense three years ago. It would have cost a fortune. But we're in this really fun place right now, in terms of technology development, where products like this do become affordable, which makes them accessible, and applications like Mic'd Up for youth sports associations are feasible." Lootens says the company's "tuned machine-learning model" is capable of quickly reviewing hours of audio and detecting even subtle moments of abuse, insults or verbal threats directed at referees. The software then catalogues the incidents into a report that is provided to referees' sport associations, which can help when it comes to holding people who mistreat referees accountable. "One of the big challenges that associations run into is ... they have a hard time enforcing their own policies the way they meant to when they wrote them, because they don't have this record of truth," Lootens said. "A lot of times their situations devolve into he-said-she-said, and so we provide them with that record of truth." Young refs 'just not staying' Both Lootens and company co-founder Tamara Jarrett have worked as referees in the past and say the level of abuse they can face is not only troubling but also detrimental to the recruitment and retention of refs starting at the youngest levels. Jarrett said kids who are 13 or 14 can make good money refereeing, but she's seen many who give it a try and then quit due to the treatment they receive. "They're just not staying," she said. "It's not the money. They're just not staying." Lootens said referee abuse also goes "grossly underreported" because of the time and effort it takes for reports to be manually filed. "We're automating that, so that associations are dealing with a lot more data," he said. "The idea being that they can now start to identify trends, versus always just responding to a specific incident." 'This is a global problem' Elements Athletics received support from Platform Calgary, a local non-profit organization that helps startups launch and grow with mentorship, advice, connections to networks and access to capital. Platform Calgary CEO Terry Rock says the organization has helped foster the city's increasingly established tech scene, and it now counts roughly 700 tech companies among its members. So far, Elements Athletics clients have been local sports associations, but Lootens hopes to grow it around the world. "We see no reason why it can't be a global product," he said.
Globe and Mail
an hour ago
- Globe and Mail
Two Healthcare Heavyweights, One Winner: UnitedHealth or CVS Health?
The healthcare sector is dominated by massive players, but few are as influential as UnitedHealth Group Incorporated UNH and CVS Health Corporation CVS. Both combine insurance and care delivery, with extensive footprints, UNH via UnitedHealthcare and Optum, and CVS through its retail pharmacies, PBM and Aetna insurance. With the sector's ongoing shake-up, from rising costs to regulatory shifts, it's high time to evaluate which stock stands out today. There are compelling cases for both: UnitedHealth's size, scale, recent drop in prices and integration appeal to growth investors, while CVS' diversification and turnaround strategy resonate with value-seekers. Let's dive deep and closely compare the fundamentals to determine which one is the stronger investment today. The Case for UnitedHealth UNH remains a massive force, delivering first-quarter revenues of $109.6???billion and adjusted net income of $6.6???billion, maintaining a 6% net margin. Wall Street had higher earnings expectations, and the company failed to properly project medical costs, prompting it to withdraw its 2025 guidance, revealing some cracks beneath the surface. Management acknowledged missteps in adapting to new Medicare Advantage risk models, which hurt margins. It missed earnings estimates once in the past four quarters and beat on the other occasions, with an average surprise of 1.2%. On the bright side, UNH's core strengths remain intact. UnitedHealthcare and Optum's cross-market integration remains effective, giving UNH a competitive moat. A 1.9% increase to 50.1 million medical members in the first quarter reflects continued expansion. However, ongoing margin pressure, elevated medical costs and ambiguity on earnings guidance suggest UNH may struggle to reignite its long-term performance trajectory. Medical costs surged 11.7% in the first quarter alone, following a 9.2% rise in 2024. We anticipate that medical expenses will grow by more than 16% in 2025. Higher-than-expected patient volumes, particularly high-acuity cases, have further strained profitability. Also, a Wall Street Journal report revealed a criminal investigation into alleged Medicare fraud. Optum Rx, UNH's pharmacy benefit manager, may also face headwinds from regulatory moves targeting pharmacy benefit management's ('PBM') pricing power. President Trump's "most-favored nation" executive order will likely affect 'middlemen' and facilitate the direct sale of drugs to patients. CVS Health's PBM, Caremark, also falls in the target zone. Nevertheless, the new CEO of UNH, Steve Hemsley, began his return to leadership by issuing a rare apology to investors following the company's first earnings miss in almost two pledged to rebuild shareholder trust and tackle escalating expenses head-on. The Case for CVS CVS reported first-quarter revenues of $94.6???billion and net income of $1.8???billion, and adjusted EPS of $2.25, well ahead of last year's $1.31, beating the Zacks Consensus Estimate by 31.6%. Several positive indicators stand out: The Health Care Benefits segment's medical benefit ratio dropped to 87.3%, down more than 300 bps year over year. This reflects better cost control in Medicare Advantage. It beat earnings estimates in each of the past four quarters with an average surprise of 18.1%. In the first quarter of 2025, the company delivered solid Medicare results, supported by higher Medicare Advantage star ratings for the 2025 payment year. Management remains confident in its 2025 pricing strategy, which reflects sensible assumptions regarding utilization trends. CVS' diversified model, spanning insurance, PBM and retail/clinics, is showing solid momentum, with steady pharmacy claims, rising retail script volumes and improved adjusted operating income across all segments. Its innovative initiatives, such as CVS CostVantage, aim to ease reimbursement pressures in retail pharmacy by enhancing pricing transparency. CVS' partnerships (like Wegovy & Novo Nordisk) and investments in primary care and digital are gaining traction. The company is also advancing technologies like voice automation, AI, and robotics to cut costs and enhance customer experience. As part of its 2025 strategy, CVS plans to close 271 retail stores, targeting over $500 million in cost savings. In contrast to UNH, CVS is executing a clear turnaround: margins are improving, guidance has been raised (with adjusted EPS forecast now $6.00-$6.20, up from $5.75-$6.00), and it is gaining analyst confidence. CVS's higher dividend yield (3.97%) means it returns more cash to shareholders relative to its stock price compared to UnitedHealth's 2.72%. How Do Zacks Estimates Compare for UNH & CVS? Zacks Consensus Estimates favor CVS at this stage. It has seen upward revisions in EPS estimates for the current year, while UNH has witnessed multiple downward revisions. The consensus estimate for CVS' 2025 earnings indicates a 12.7% increase from a year ago, while the same for revenues suggests 3.5% growth. On the other hand, the Zacks Consensus Estimate for UNH's 2025 revenues indicates 12.3% year-over-year growth, but the same for EPS signals a massive 19.5% decline. Valuation: UNH vs. CVS Valuation also favors CVS. While UNH trades at a forward P/E of 12.98X, CVS trades at a more modest 10.31. This valuation gap gives CVS Health a more attractive risk-reward profile. In contrast, UNH's premium pricing could limit near-term upside unless it delivers clear margin improvements. Price Performance Comparison Over the year-to-date period, UNH faced selloffs tied to medical costs and investigation concerns. Its shares plunged 39% during the same time. Meanwhile, CVS shares have jumped 49.4%, outperforming the broader industry and the S&P 500 Index, supported by stronger earnings momentum and clearer guidance. Price Performance – UNH, CVS, Industry & S&P 500 Conclusion Though UnitedHealth remains a healthcare powerhouse with unmatched integration and scale, recent cost-control misfires and guidance uncertainties weigh on its near-term outlook. On the other hand, CVS is executing a well-defined turnaround, its margins are improving, positive estimate revisions are rolling in, and shares remain attractively valued. For investors seeking current upside potential and a better value play, CVS Health clearly holds the edge. Its diversified model, execution on cost control and analyst upgrades make it a stronger pick in today's healthcare landscape. UnitedHealth currently carries a Zacks Rank #5 (Strong Sell), while CVS Health has a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in the coming year. While not all picks can be winners, previous recommendations have soared +112%, +171%, +209% and +232%. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. Today, See These 5 Potential Home Runs >> UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report CVS Health Corporation (CVS): Free Stock Analysis Report
